Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | MSCI ACWI IMI Genomic Innovation Select Screened 100 |
| Investment focus | Aktien, Welt, Gesundheitswesen, Sozial/Nachhaltig |
| Fund size | EUR 8 m |
| Total expense ratio | 0,30% p.a. |
| Replication | Physical (Full replication) |
| Legal structure | ETF |
| Strategy risk | Long-only |
| Sustainability | Ja |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in EUR) | 20,14% |
| Inception/ Listing Date | 12. Juli 2022 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Irland |
| Fund Provider | Xtrackers |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | State Street Custodial Services (Ireland) Limited |
| Investment Advisor | DWS Investments UK Limited |
| Custodian Bank | State Street Custodial Services (Ireland) Limited, Dublin 2 |
| Revision Company | Pricewaterhouse Coopers |
| Fiscal Year End | 31. Dezember |
| Swiss representative | DWS CH AG |
| Swiss paying agent | Deutsche Bank (Suisse) SA |
| Germany | 30% Teilfreistellung |
| Switzerland | ESTV Reporting |
| Austria | Meldefonds |
| UK | UK Reporting |
| Indextype | - |
| Swap counterparty | - |
| Collateral manager | |
| Securities lending | Yes |
| Securities lending counterparty |
| Roche Holding AG | 5,53% |
| Vertex Pharmaceuticals | 4,97% |
| Natera | 4,63% |
| Eli Lilly & Co. | 4,49% |
| Lonza Group AG | 4,43% |
| Danaher Corp. | 4,29% |
| Abbott Laboratories | 4,05% |
| Illumina, Inc. | 3,90% |
| Agilent Technologies | 3,59% |
| Insmed | 3,46% |
| USA | 69,15% |
| Schweiz | 11,22% |
| China | 5,84% |
| Sonstige | 13,79% |
| Gesundheitswesen | 88,41% |
| Sonstige | 11,59% |
| Broker | Testurteil | Gebühr pro Sparrate | Depotgebühr | |
|---|---|---|---|---|
| 0,00 € | 0,00 € | Zum Angebot* | |
| 0,00 € | 0,00 € | Zum Angebot** | |
| 0,00 € | 0,00 € | Zum Angebot* | |
| 0,00 € | 0,00 € | Zum Angebot* | |
| 0,00 € | 0,00 € | Zum Angebot* |
| Lfd. Jahr | -2,82% |
| 1 Monat | -1,38% |
| 3 Monate | -3,73% |
| 6 Monate | +2,80% |
| 1 Jahr | +18,32% |
| 3 Jahre | +1,56% |
| 5 Jahre | - |
| Seit Auflage (MAX) | -12,16% |
| 2025 | +5,48% |
| 2024 | +3,95% |
| 2023 | -7,06% |
| 2022 | - |
| Volatilität 1 Jahr | 20,14% |
| Volatilität 3 Jahre | 17,75% |
| Volatilität 5 Jahre | - |
| Rendite zu Risiko 1 Jahr | 0,91 |
| Rendite zu Risiko 3 Jahre | 0,03 |
| Rendite zu Risiko 5 Jahre | - |
| Maximum Drawdown 1 Jahr | -13,31% |
| Maximum Drawdown 3 Jahre | -25,40% |
| Maximum Drawdown 5 Jahre | - |
| Maximum Drawdown seit Auflage | -35,94% |
| Börsennotierung | Handelswährung | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | XGEN | - - | - - | - |
| Borsa Italiana | EUR | XGEN | XGEN IM XGENEUIV | XGEN.MI XGENEURINAV=SOLA | |
| London Stock Exchange | USD | XGEN | XGEN LN XGENUSIV | XGEN.L XGENUSDINAV=SOLA | |
| London Stock Exchange | GBP | XGES | XGES LN XGENCHIV | XGES.L XGENCHFINAV=SOLA | |
| XETRA | EUR | XGEN | XGEN GR | XGEN.DE |
| Fondsname | Fondsgröße in Mio. € (AuM) | TER p.a. | Ausschüttung | Replikation |
|---|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF | 862 | 0,40% p.a. | Thesaurierend | Sampling |
| VanEck Genomics and Healthcare Innovators UCITS ETF A | 11 | 0,35% p.a. | Thesaurierend | Vollständig |